R
Raman Preet Kaur
Researcher at University of Health Science
Publications - 2
Citations - 347
Raman Preet Kaur is an academic researcher from University of Health Science. The author has contributed to research in topics: Internal medicine & Hazard ratio. The author has an hindex of 1, co-authored 1 publications receiving 291 citations.
Papers
More filters
Journal ArticleDOI
MicroRNA therapeutics: Discovering novel targets and developing specific therapy.
Ajay Francis Christopher,Raman Preet Kaur,Gunpreet Kaur,Amandeep Kaur,Vikas Gupta,Parveen Bansal +5 more
TL;DR: A large number of miRNAs have entered the preclinical and clinical stage and soon might be available in the market for use in humans, and many more are in the development stage.
Journal ArticleDOI
International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System
Matthias Lechner,Yoko Takahashi,Mario Turri-Zanoni,Marco Ferrari,Jacklyn Liu,Nicholas Counsell,Davide Mattavelli,Vittorio Rampinelli,William Vermi,David A. Lombardi,Rami E. Saade,Ki Wan Park,Volker Hans Schartinger,Alessandro Franchi,Carla Facco,Fausto Sessa,Simonetta Battocchio,Tim R. Fenton,Francis Vaz,Paul O'Flynn,David Howard,Paul Stimpson,Simon Wang,Saiful Alam Hannan,Samit Unadkat,Jonathan Hughes,Raghav C. Dwivedi,Cillian T Forde,Premjit S Randhawa,Simon Gane,Jonathan Joseph,Peter J. Andrews,Manas Dave,Jason C. Fleming,David J Thomson,Tianyu Zhu,Andrew E. Teschendorff,G.T. Royle,C Steele,Joaquin E. Jimenez,Jan Laco,Eric W. Wang,Carl H. Snyderman,Peter D. Lacy,Robbie S. R. Woods,James P. O'Neill,Anirudh Saraswathula,Raman Preet Kaur,Tianna Zhao,Murugappan Ramanathan,Gary L. Gallia,Nyall London,Quynh-Thu Le,Robert B. West,Zara M. Patel,Jayakar V. Nayak,Peter H. Hwang,Mario Hermsen,José Luis Llorente,Fabio Facchetti,Piero Nicolai,Paolo Bossi,Paolo Castelnuovo,Amrita Jay,Dawn Carnell,Martin Forster,Diana Bell,Valerie J. Lund,Ehab Y. Hanna +68 more
TL;DR: The potential utility of further stratifying the T3 stage by sinus involvement is demonstrated and promising data on the benefit of immune checkpoint inhibitors for recurrent, persistent, or metastatic disease is presented, with implications for future clinical trials in this field.